Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial.
暂无分享,去创建一个
D. Kerr | D. Bissett | D. Jodrell | J. Paul | R. Leonard | G C Wishart | D Bissett | J Paul | D Jodrell | A Harnett | T Habeshaw | D J Kerr | M A Macham | M Soukop | R C Leonard | T. Habeshaw | G. Wishart | A. Harnett | M. Soukop | M. Macham | J. Paul
[1] P. Workman,et al. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. , 1989, Biochemical pharmacology.
[2] I. Pastan,et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[3] P. Meltzer,et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] D. Kerr,et al. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer. , 1990, British Journal of Cancer.
[5] R. Ozols,et al. The anthracycline antineoplastic drugs. , 1981, The New England journal of medicine.
[6] G. Wishart,et al. Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo. , 1992, European journal of cancer.
[7] B. Sikic,et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] C. McArdle,et al. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. , 1990, British Journal of Cancer.
[9] S. Kaye,et al. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] P. Sonneveld,et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin , 1992, The Lancet.
[11] D. V. Von Hoff,et al. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. , 1992, Journal of the National Cancer Institute.
[12] V. Ling,et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. , 1991, The New England journal of medicine.
[13] S. Kaye. P glycoprotein (P-gp) and drug resistance--time for reappraisal? , 1993, British Journal of Cancer.
[14] F. Kwiatkowski,et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. , 1991, Journal of the National Cancer Institute.
[15] I. Pastan,et al. Expression of the Multidrug Resistance Gene in Human Cancer , 1991 .
[16] B. Sikic,et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] T. Tsuruo,et al. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. , 1984, Cancer research.
[18] T. Grogan,et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Rubens,et al. Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.